although these results must be interpreted with caution because they were obtained in consecutive nonrandomized studies , the use of itraconazole for antifungal prophylaxis in granulocytopenic patients seems to be a major advance and to be especially advantageous in hospitals , where the incidence of fatal aspergillosis in these patients is high .
C0064113
itraconazole
C0004030
aspergillosis